Description:
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus
abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or
metastatic renal cell carcinoma (RCC).
Title
- Brief Title: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- Official Title: A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)
Clinical Trial IDs
- ORG STUDY ID:
XYN-602
- NCT ID:
NCT03592472
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| Pazopanib | Votrient® | Pazopanib plus abexinostat |
| Abexinostat | PCI-24781 | Pazopanib plus abexinostat |
Purpose
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus
abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or
metastatic renal cell carcinoma (RCC).
Detailed Description
In this randomized, Phase 3, double-blind, placebo-controlled study, patients will be
randomized 2:1 to receive either a combination of pazopanib plus abexinostat or pazopanib
plus placebo. At the time of disease progression, patient treatment assignment will be
unblinded, and those patients randomized to the pazopanib plus placebo treatment arm will
have the option of crossing over to receive treatment with a combination of pazopanib plus
abexinostat. After providing written informed consent, patients will be screened for study
eligibility within 28 days before their first dose of study drug. After screening
assessments, patients who are eligible for inclusion in the study will be randomized and
receive their first dose of study drug on Cycle 1 Day 1 (C1D1), within 7 days of
randomization. A treatment cycle is 28 days in length. Patients may continue to receive study
drug until any of the following events: the development of IRC-verified radiographic
progression as assessed by RECIST version 1.1, clinical disease progression, unacceptable
toxicity, another discontinuation criterion is met, withdrawal of consent, or closure of the
study by the sponsor. No maximum duration of therapy has been set.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Pazopanib plus abexinostat | Experimental | Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day. | |
| Pazopanib plus placebo | Placebo Comparator | Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day. | |
Eligibility Criteria
Inclusion Criteria:
To be enrolled in the study, patients will be required to meet all of the following
criteria:
- Patients aged ≥ 18 years at time of study entry.
- Patients have histologically confirmed RCC with clear cell component.
- Patients have locally advanced and unresectable or metastatic disease.
- Measurable disease as assessed only by the investigator (not verified by IRC)
according to RECIST version 1.1.
- Patients must not have had any prior vascular endothelial growth factor (VEGF)
tyrosine kinase inhibitor treatment in either (neo)adjuvant or locally
advanced/metastatic setting. Up to 1 line of prior cytokine or immune checkpoint
inhibitor treatment is allowed in either the (neo)adjuvant or metastatic setting
provided screening scans indicate progressive disease (PD) during or following
completion of treatment.
- Patients have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patients have adequate baseline organ function.
- Patients have adequate baseline hematologic function
- Patient must be at least 2 weeks from last systemic treatment or dose of radiation
prior to date of randomization.
Exclusion Criteria:
Patients who meet any of the following criteria at Screening will not be enrolled in the
study:
- Has persistent clinically significant toxicities (Grade ≥ 2; per NCI CTCAE version 5
from previous anticancer therapy (excluding alopecia which is permitted and excluding
Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are
not considered clinically significant by the investigator, and can be managed with
available medical therapies).
- Has untreated central nervous system (CNS) metastases. Patients with treated CNS
metastases are eligible provided imaging demonstrates no new or progressive metastases
obtained at least 4 weeks following completion of treatment. CNS imaging during
Screening is not required unless clinically indicated.
- Has an additional malignancy requiring treatment within the past 3 years. Patients
with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin
cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma.
- Poorly controlled hypertension, defined as systolic blood pressure ≥ 160 or diastolic
blood pressure ≥ 100 mmHg. Use of anti-hypertensives and rescreening is permitted.
- A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to
randomization.
- Has a QTcF interval > 480 msec.
- New York Heart Association Class III or IV congestive heart failure.
- Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter,
prior to first dose of study drug.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Progression-free survival (PFS) |
| Time Frame: | From randomization date to date of first documentation of progression OR death (up to approximately 4 years). |
| Safety Issue: | |
| Description: | To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by blinded Independent Review Committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Secondary Outcome Measures
| Measure: | PFS by investigator assessment according to RECIST version 1.1. |
| Time Frame: | From randomization date to date of first documentation of progression OR death (up to approximately 4 years). |
| Safety Issue: | |
| Description: | To compare the PFS between treatment arms by investigator assessment. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assessed by IRC according to RECIST version 1.1. |
| Measure: | Overall survival (OS) |
| Time Frame: | From progression or end of study, every 3 months follow up until death, patient withdrawal from study follow-up, or study closure, whichever occurs first (up to approximately 4 years). |
| Safety Issue: | |
| Description: | OS is defined as the interval between date of randomization and date of death. The main objective was to compare the OS between treatment arms by investigator assessment. |
| Measure: | Adverse events by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 |
| Time Frame: | From Day 1 until end of treatment visit (up to approximately 4 years). |
| Safety Issue: | |
| Description: | To characterize the safety profile of pazopanib in combination with abexinostat. |
| Measure: | Objective response rate (ORR) |
| Time Frame: | Screening, Cycle 3 Day 1 (C3D1), Cycle 5 Day 1 (C5D1), Cycle 7 Day 1 (C7D1), and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years). |
| Safety Issue: | |
| Description: | ORR is defined as the proportion of patients with objective evidence of CR or PR by RECIST version 1.1. The main objective was to compare the ORR between treatment arms by investigator assessment. |
| Measure: | Duration of response (DOR) |
| Time Frame: | Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years). |
| Safety Issue: | |
| Description: | DOR is defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause by RECIST version 1.1. The main objective was to compare the DOR between treatment arms by investigator assessment. |
| Measure: | ORR by RECIST version 1.1 in cross-over patient population |
| Time Frame: | Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years). |
| Safety Issue: | |
| Description: | To describe the ORR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment. |
| Measure: | DOR by RECIST version 1.1 in cross-over patient population |
| Time Frame: | Screening, Cycle 3 Day 1 (C3D1), C5D1, C7D1, and on Day 1 of every third cycle (each cycle is 28 days in length) thereafter until end-of-treatment visit (up to approximately 4 years). |
| Safety Issue: | |
| Description: | To describe the DOR in patients who cross over to receive pazopanib plus abexinostat at the time of disease progression on pazopanib monotherapy by investigator assessment. |
| Measure: | Mean change from Baseline in Functional Assessment of Cancer Therapy Kidney System Index (FKSI-19) scores |
| Time Frame: | First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) until end-of-treatment visit (up to approximately 4 years). |
| Safety Issue: | |
| Description: | To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and health-related quality of life (QoL) by investigator assessment. QoL will be assessed by measuring change from baseline in FKSI-19. The FKSI-19 assesses disease-related symptoms experienced in the past 7 days. Patients are asked to respond to 12 questions ("I have a lack of energy," "I feel pain," for example) by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much; possible total score of 0 to 48). |
| Measure: | Mean change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT-F) scores |
| Time Frame: | First day of treatment Cycle1, Cycle 2, Cycle 6 (each cycle is 28 days in length) and at end-of-treatment visit (up to approximately 4 years). |
| Safety Issue: | |
| Description: | To assess the impact of pazopanib with or without abexinostat on disease-related symptoms and QoL by investigator assessment. QoL will be assessed by measuring change from baseline in FACIT-F. The FACIT-F scale measures QoL experienced in the past seven days. The measurement consisted of 5 domains (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns) assessed on a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). |
Details
| Phase: | Phase 3 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | Xynomic Pharmaceuticals, Inc. |
Trial Keywords
- Renal Cell Carcinoma
- Progression-free survival
- Abexinostat
- Pazopanib
- RECIST
- Cancer therapy
Last Updated
May 12, 2021
